Background Massive intraoperative bleeding (IBL) in liver transplantation (LT) poses serious risks and strains healthcare resources necessitating better predictive models for risk stratification. As traditional models often fail to capture the complex, non-linear patterns underlying bleeding risk, this study aimed to develop data-driven machine learning models for predicting massive IBL during LT using preoperative factors.

Methods Two hundred ninety consecutive LT cases from a prospective database were analyzed. Logistic regression models were built using 73 preoperative demographic and laboratory variables to predict massive IBL (≥ 80 mL/kg). The dataset was randomly split (70% training, 30% testing). The model was trained and validated through three-fold cross-validation, with backward stepwise feature selection iterated 100 times across unique random splits. The final model, based on a high stability index, was evaluated using the area under the curve (AUC).

Results Massive IBL was observed in 141 patients (48.6%). In standard logistic regression, significant differences were found in 42 of 73 factors between groups stratified by massive IBL, however, substantial multicollinearity limited interpretability. In the feature selection across 100 iterations, the data-driven model achieved an average AUC of 0.840 in the validation and 0.738 in the test datasets. The final model, based on 11 selected features with a high stability index, achieved an AUC of 0.844. An easy-to-use online risk calculator for massive IBL was developed and is available at: https://tai1wakiya.shinyapps.io/ldlt_bleeding_ml/.

Conclusions Our findings highlight the potential of machine learning in capturing complex risk factor interactions for predicting massive IBL in LT.

The authors have declared no competing interest.

The author(s) received no specific funding for this work.

I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.

Not Applicable

The details of the IRB/oversight body that provided approval or exemption for the research described are given below:

This study was approved by the Ethics Committee of Jichi Medical University (Ethics Committee Approval Case Number 20-008). Informed consent was obtained in the form of opt-out on our website (https://www.jichi.ac.jp/transplant/contents/disclosure.html), with the approval of the Ethics Committee of Jichi Medical University.

I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.

Not Applicable

I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).

Not Applicable

I have followed all appropriate research reporting guidelines, such as any relevant EQUATOR Network research reporting checklist(s) and other pertinent material, if applicable.

Not Applicable

Data cannot be shared publicly because of institutional policy and patient confidentiality. Data are available from the Jichi Medical University Institutional Ethics Committee (contact via https://www.jichi.ac.jp/kenkyushien/clinical/clinical_human/) for researchers who meet the criteria for access to confidential data.